Autolus Therapeutics plc (AUTL)
NASDAQ: AUTL · Real-Time Price · USD
1.580
-0.040 (-2.47%)
At close: Oct 22, 2026, 4:00 PM EDT
1.600
+0.020 (1.27%)
After-hours: Oct 22, 2026, 7:30 PM EDT
Autolus Therapeutics Revenue
Autolus Therapeutics had revenue of $45.69M in the quarter ending June 30, 2026, with 118.37% growth. This brings the company's total for the last twelve months to $117.39M, up 292.16% year-over-year. In the year 2025, Autolus Therapeutics had annual revenue of $75.39M with 644.94% growth. That makes Autolus Therapeutics the 21,429th largest company in the world by revenue and 3,186th in the United States.
Revenue (ttm)
$117.39M
Revenue Growth
+292.16%
P/S Ratio
3.58
Revenue / Employee
$155,690
Employees
754
Market Cap
420.54M
Revenue by Geography
- United States of America 75.34M 99.9%
- Europe 50.00K 0.1%
Fiscal year ended Dec 31, 2025 See the full Autolus Therapeutics breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 75.39M | 65.27M | 644.94% |
| Dec 31, 2024 | 10.12M | 8.42M | 496.00% |
| Dec 31, 2023 | 1.70M | -4.68M | -73.38% |
| Dec 31, 2022 | 6.38M | 4.87M | 323.23% |
| Dec 31, 2021 | 1.51M | 1.27M | 522.73% |
| Dec 31, 2020 | 242.00K | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Sep 30, 2018 | - | - | - |
| Sep 30, 2017 | - | - | - |
| Sep 30, 2016 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| ARS Pharmaceuticals | 116.93M |
| Assembly Biosciences | 74.85M |
| Prothena Corporation | 54.53M |
| Allogene Therapeutics | 4.64M |
| ProKidney | 818.00K |
| Avalo Therapeutics | 59.00K |
| Altimmune | 31.00K |
AUTL News
- 17 days ago - Autolus Therapeutics to Present Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026 - GlobeNewsWire
- 4 weeks ago - Autolus Therapeutics management to meet virtually with William Blair - TheFly
- 5 weeks ago - Autolus Therapeutics Registration statement: Registration filing - Filings
- 5 weeks ago - Autolus Therapeutics files to sell 3.5M American Depositary Shares for holders - TheFly
- 6 weeks ago - Autolus Therapeutics granted RMAT designation for obecabtagene autoleucel - TheFly
- 6 weeks ago - Autolus Therapeutics Announces FDA RMAT Designation Granted to Obe-cel for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis - GlobeNewsWire
- 2 months ago - Autolus Therapeutics Slides: Corporate presentation - Filings
- 2 months ago - Autolus Therapeutics Earnings Call Transcript: Q2 2026 - Transcripts